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Abstract: High-resolution magic angle spinning (HR-MAS) magnetic
resonance (MR) spectroscopy data may serve as a biomarker for breast
cancer, with only a small volume of tissue sample required for assess-
ment. However, previous studies utilized only a single tissue sample
from each patient. The aim of this study was to investigate whether
intratumoral location and biospecimen type affected the metabolic
characterization of breast cancer assessed by HR-MAS MR
spectroscopy
This prospective study was approved by the institutional review
board and informed consent was obtained. Preoperative core-needle
biopsies (CNBs), central, and peripheral surgical tumor specimens were
prospectively collected under ultrasound (US) guidance in 31 patients
with invasive breast cancer. Specimens were assessed with HR-MAS
MR spectroscopy. The reliability of metabolite concentrations was
evaluated and multivariate analysis was performed according to intra-
tumoral location and biospecimen type.
There was a moderate or higher agreement between the relative
concentrations of 94.3% (33 of 35) of metabolites in the center and, Seho Park, MD, ark, MD,
in Jung Kim, MD, PhD
between the concentrations of phosphocholine (PC) and phosphoetha-
nolamine (PE) in the center and periphery. The concentrations of
several metabolites (adipate, arginine, fumarate, glutamate, PC, and
PE) had no significant agreement between the CNB and central
surgical specimens.
In conclusion, most HR-MAS MR spectroscopic data do not differ
based on intratumoral location or biospecimen type. However, some
metabolites may be affected by specimen-related variables, and cau-
tion is recommended in decision-making based solely on metabolite
concentrations, particularly PC and PE. Further validation through
future studies is needed for the clinical implementation of these
biomarkers based on data from a single tissue sample.
(Medicine 95(15):e3398)
Abbreviations: CNB = core-needle biopsy, ER = estrogen receptor,
HER2 = human epidermal growth factor receptor 2, HR-MAS =
high-resolution magic angle spinning, ICC = intraclass correlation
coefficient, IHC = immunohistochemistry, MR = magnetic
resonance, PC = phosphocholine, PE = phosphoethanolamine,
PLS-DA = partial least squares discriminant analysis, PR =
progesterone receptor, US = ultrasound.
INTRODUCTION
M agnetic resonance (MR) spectroscopy is a promisingmodality that can quantitatively analyze metabolic altera-
tions in breast cancer and help identify potential targets for
personalized therapy.1 Although in vivo MR spectroscopy can
provide information that encompasses the entire tumor lesion,
the breast spectra typically can only display a single metabolite
peak representing the total choline (tCho).2 However, recent
advances have enabled the detection of various metabolites in
breast cancer tissue using high-resolution magic angle spinning
(HR-MAS) MR spectroscopy. HR-MAS MR spectroscopy is a
nondestructive technique that provides spectra with multiple
peaks from intact tissue.3 Through the discrimination and
quantification of choline-containing compounds and various
other metabolites, HR-MAS MR spectra provide a vast amount
of biological information. Previous studies using HR-MAS MR
spectroscopy data have reported that the metabolic profiles of
breast cancer specimens differ according to clinicopathologic
factors and may serve as a potential marker for tumor
aggressiveness.4–8
Heterogeneity within individual tumors has been exten-
sively reported in both morphological and genomic studies.
Immunomarkers including human epidermal growth factornd microRNA expression levels have
terogeneity in breast cancer, suggesting
presentative larger tumor samples or at
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several different tumor locations may be required for accurate
assessment.9–12 In addition, there have been concerns that
specimen type (such as in vivo core-needle biopsy [CNB]
sampling and ex vivo surgical sampling) may affect biomarkers
or metabolic profiling. In a recent study that assessed in vivo
CNB biopsies and central and peripheral surgical breast cancer
specimens with reverse-phase protein arrays and immunohis-
tochemistry (IHC), 86% of the proteomic biomarkers did not
show significant intratumoral heterogeneity, but 37% of the
biomarkers differed between the CNB and surgical speci-
mens.13 As HR-MAS MR spectroscopy requires only a small
volume of tissue sample, it is unclear whether these results can
be considered to be representative of the entire lesion. In
addition, to the best of our knowledge, no studies have directly
compared HR-MAS spectroscopy data between CNB and sur-
gical specimens in patients with breast cancer.
Therefore, the purpose of this study was to investigate
whether intratumoral location and biospecimen type (in vivo
Park et alcollection of core biopsy samples or ex vivo collection of
surgical tumor samples) affect the metabolic characterization
of breast cancer as assessed by HR-MAS MR spectroscopy.
MATERIALS AND METHODS
Study Population and Specimen Acquisition
This prospective study was approved by the institutional
review board of Yonsei University College of Medicine, and
written consent was obtained from each patient. Between July
2014 and January 2015, 71 female patients who fulfilled the
following inclusion criteria were initially enrolled: 20 years of
age or older, not pregnant at the time of diagnosis, no history of
breast cancer, and had either undergone ultrasound (US)-guided
CNB at our institution for breast lesions assessed as category 4
or 5 and larger than 1 cm in diameter on US images, or were
referred to our hospital after being diagnosed with breast cancer.
Nine patients with benign pathology results on CNB and 27
patients fromwhom surgical tumor samples were not obtainable
immediately following surgical removal were excluded. Of the
remaining 35 patients, 28 patients underwent US-guided CNB
preoperatively at our institution and 7 patients were referred to
our hospital after being diagnosed with breast cancer. From the
28 patients who were diagnosed at out institution, 1 CNB
specimen was obtained at the time of preoperative US-guided
CNB and was included in our study. For all 35 patients, 2 core
tissue samples were obtained from the tumor under US guidance
following surgical removal. Thus, 98 core tissue samples from
35 patients were initially included in our study – 28 tissue
samples obtained preoperatively in 28 patients and 70 tissue
samples obtained from surgical specimens from 35 patients.
Our research team was contacted at the beginning of the
enrolled patients’ surgeries, and a member from the team
prepared a portable icebox containing ice blocks and an US
unit for biopsy. Following surgical removal of the tumor, the
surgical tumor specimens were immediately placed on top of the
ice blocks and carried to the US unit. Two tissue samples were
obtained under US guidance using a 14-guage dual-action
semiautomatic core biopsy needle (Stericut with coaxial guide,
TSK Laboratory, Tochigi, Japan), obtained from both the tumor
center and periphery. The core tissue sample from the tumor
center was obtained by targeting the epicenter of the tumor with
a core biopsy needle. In large cancers with solid and cystic
components, the homogeneously solid areas were targeted. The
core tissue sample from the periphery of the tumor was obtained
2 | www.md-journal.comfrom within the tumor boundary seen on US. In 1 patient who
was diagnosed with breast cancer at our institution, 2 core tissue
samples were later obtained from the center of the surgical
tumor specimen, as the periphery of the lesion was primarily
cystic. For HR-MAS MR spectroscopy, all tissue samples were
put in a cryogenic vial and immersed in liquid nitrogen
immediately after biopsy. Samples were stored at 162 8C
for 1 to 7 months prior to HR-MAS MR spectroscopy. After
HR-MASMR spectroscopy, all 98 tissue samples were assessed
by hematoxylin and eosin (H&E) staining and subsequently 7
samples with no tumor cells on H&E staining were excluded.
Consequently, 4 patients had only 1 sample and were also
excluded from the study. In total, 87 tissue samples from
31 patients (mean age 54.2 years; range 31–75 years) were
included, which composed our study population.
HR-MAS MR Spectroscopy
HR-MAS MR spectroscopy was performed on the tumor
specimens using a nuclear magnetic resonance (NMR) spec-
trometer (Agilent, VNMRS 600). The proton NMR frequency
was set to 600.17MHz (11.74T) and the temperature was set to
26 8C. After defrost, the tissue samples were weighed and
placed in an HR-MAS nanoprobe (Agilent, Walnut Creek,
CA), with a total cell volume of 40mL. Samples weighing
an average of 8.19mg were put in the cell with the remainder
filled with D2O containing 2mM trimethylsilyl propionic acid
(TSP). An inverse-detection type probe with a single Z gradient
coil was used. Analysis was performed using a Carr–Purcell–
Meiboom–Gill (CPMG) pulse sequence to apply a T2 filter. All
spectra were obtained at a spinning rate of 2 kHz. The spectral
acquisition parameters were as follows: 16.384K complex data
points, 9615.4Hz sweep width, 1.704-s acquisition time, 1.0-s
relaxation delay, 2.0-s presaturation time, 256 number of tran-
sients, and total acquisition time of 16 minutes and 18 seconds.
Each spectrum was processed and analyzed using Chenomx
NMR suite 7.1 software (Chenomx Inc., Canada). Postproces-
sing included Fourier transformation, phasing, and baseline
correction. Chemical shifts were referenced in relation to the
TSP signal at 0.00 ppm. Quantification was performed by
comparing the concentration of the metabolites to the concen-
tration of the TSP in each sample cell.
Histopathologic Analysis
All 31 tumors were pathologically diagnosed as malignant
based on CNB prior to surgery. The final histopathologic results
after surgery were used as reference standards. Pathological
data including histologic tumor size, nuclear grade, histologic
grade, and lymph node metastasis were obtained from the final
pathologic reports. All samples were fixed in 10% buffered
formalin and paraffin. The hematoxylin and eosin (H&E)-
stained slides for each case were analyzed by experienced
pathologists. The histologic grade of each tumor was deter-
mined with the modified Bloom–Richardson classification.14
Information on the expression status of the estrogen receptor
(ER), progesterone receptor (PR), HER2, and Ki-67 status were
obtained from the CNB specimens. IHC analyses for ER, PR,
HER2, and Ki-67 were performed using tissue blocks. ER and
PR positivity were defined as the presence of at least 10%
positive tumor nuclei in the sample on testing.15 The IHC
staining results for HER2 were scored as 0, 1þ, 2þ, or 3þ
Medicine  Volume 95, Number 15, April 2016according to the number of cells stained positively on the
membrane. Tumors with a score of 3þ were classified as
HER2-positive, and tumors with scores of 0 or 1þ were
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peripheral surgical specimens (97.1%, 34 of 35) and between
the CNB and central surgical specimens (94.3%, 33 of 35)
(Table 3).
TABLE 1. Clinicopathologic Characteristics of the 31 Patients
With Invasive Breast Cancers
Clinicopathologic Variables Patients, %
Age (mean SD) Years 54.2 12.8
Histologic grade Low 14 (45.2)
High 17 (54.8)
Nuclear grade Low 17 (54.8)
High 14 (45.2)
ER status Negative 10 (32.3)
Positive 21 (67.7)
PR status Negative 20 (64.5)
Positive 11 (35.5)
HER2 status Negative 23 (74.2)
Positive 8 (25.8)
Triple negativity Negative 26 (83.9)
Positive 5 (16.1)
Ki-67 status Low 11 (35.5)
High 20 (64.5)
Immunohistochemistry subtype Luminal A 9 (29.0)
Luminal B 8 (25.8)
Luminal-HER2 4 (12.9)
HER2 enriched 5 (16.1)
Triple negative 5 (16.1)
Tumor size (meanSD) mm 22.0 9.7
Lymph node metastasis Negative 20 (64.5)
Positive 11 (35.5)
Continuous variables (age, tumor size) are presented as
Inclassified as HER2-negative. Gene amplification using fluor-
escence in situ hybridization was performed in tumors with a
score of 2þ to determine HER2 status.16,17 Triple negative breast
cancer was defined as a tumor negative for ER, PR, and HER2.
The IHC staining results for Ki-67 were scored according to the
number of cells with positively stained nuclei andwere expressed
as percentages of the total tumor cells. Staining results for Ki-67
were classified as low <14% and high 14%.18
Statistical Analysis
The reliability of HR-MASMR spectroscopic values of the
metabolite concentrations (acetate, adipate, alanine [Ala], argi-
nine [Arg], asparagine [Asn], aspartate [Asp], betaine, choline
[Cho], creatine [Cr], ethanolamine, fumarate, glucose, gluta-
mate [Glu], glutamine [Gln], glycerol, glycine [Gly], glycer-
ophosphcholine [GPC], histidine [His], isoleucine [Ile], lactate,
leucine [Leu], lysine [Lys], methionine [Met], phosphocholine
[PC], phosphoethanolamine [PE], phenylalanine [Phe], proline
[Pro], serine [Ser], taurine, total choline [tCho, the sum of Cho,
PC, and GPC], threonine [Thr], tyrosine [Tyr], uracil, valine
[Val], and myo-inositol [m-Ins]) among all 3 specimen types
(CNB samples collected in vivo vs central surgical tumor
samples collected ex vivo vs peripheral surgical tumor samples
collected ex vivo) was assessed using the intraclass correlation
coefficient (ICC). Post hoc analysis between the following
groups were performed using ICCs with Bonferroni correction:
CNB samples collected in vivo versus central surgical tumor
samples collected ex vivo, and central surgical tumor samples
collected ex vivo versus peripheral surgical tumor samples
collected ex vivo. ICC values that did not include 0 in their
respective 95% confidence intervals were considered to show
statistically significant agreement. ICC values in the following
ranges were considered to indicate poor (0–0.2), fair (0.21–
0.4), moderate (0.41–0.60), substantial (0.61–0.80), or almost
perfect agreement (0.81–1.00).19 Differences in HR-MAS MR
spectroscopic values according to intratumoral location and
biospecimen type were analyzed using the paired t test between
CNB samples versus central surgical samples and between
central surgical samples versus peripheral surgical samples.
Statistical analysis was conducted using statistical software
(version 20.0; SPSS, Chicago, IL). A 2-tailed P value less than
0.05 indicated a statistically significant difference.
To evaluate whether specimen type affected the metabolic
profiling of breast cancer based on multivariate data analysis,
we performed multivariate analysis of the spectral data using
Matlab (MathWorks, Natick, MA), SIMCA-P 12.0 (Umetrics,
Sweden), and Excel (Microsoft, Seattle, WA) programs. Multi-
variate partial least squares discriminant analysis (PLS-DA)
was performed to evaluate whether different specimen types had
similar performance in distinguishing patient groups by hor-
mone receptor status (ER, PR, and HER2), for which previous
studies have reported clear separation using multivariate
models.4,5,7 To avoid over-fitting of the statistical model, class
discrimination models were built until cross-validated predict-
ability values did not increase significantly. Signals contributing
to class discrimination were identified by an S-plot, with
identification of the corresponding HR-MAS MR spectral
data using Chenomx (Spectral database; Edmonton, Alberta,
Canada) software and an in-house database.
Medicine  Volume 95, Number 15, April 2016RESULTS
The mean tumor size of the 31 malignant breast lesions
was 21.8mm (range, 11–46mm). The most common tumor
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.type was invasive ductal carcinoma (n¼ 28) and other cancer
types were 2 mixed invasive ductal carcinoma and invasive
lobular carcinoma, and 1 mixed mucinous carcinoma and
invasive micropapillary carcinoma. The clinicopathologic data
of the 31 malignant breast lesions from the 31 patients are
presented in Table 1.
Of the 35metabolites, 94.3% (33 of 35) showed amoderate
or higher level of agreement between the central and peripheral
surgical specimens (Table 2). Substantial to almost perfect
agreement was seen in 60.0% of the metabolites (21 of 35).
However, PC (ICC 0.194, 95%CI,0.173–0.514) and PE (ICC
0.241, 95% CI, 0.125–0.549) did not show significant agree-
ment between the tumor center and periphery.
Between CNB and central surgical specimens, 82.9% (29
of 35) of the metabolites showed significant agreement, with
80.0% (28 of 35) showing a moderate or higher level of
agreement. Among all 3 specimen types, all of the metabolites
showed a fair or higher level of agreement, with 82.9% (29 of
35) showing a moderate or higher level of agreement (Figures 1
and 2). The 17.1% (6 of 35) of metabolites showing fair
agreement among all 3 specimen types also showed fair or
no significant agreement between the central and peripheral
surgical specimens or between the CNB and central surgical
specimens. Using the paired t test, most of the metabolites
showed no significant difference between the central and
tratumoral Agreement of Breast Cancer Metabolic Characterizationmean standard deviation. ER¼ estrogen receptor, HER2¼ human
epidermal growth factor receptor 2, PR¼ progesterone receptor,
SD¼ standard deviation.
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TABLE 2. Reliability of HR-MAS MR Spectroscopic Values Among Specimen Types
Metabolite
Scenter Vs Speriphery CNB Vs Scenter All Specimen Types
ICC (95% CI) ICC (95% CI) ICC (95% CI)
Acetate 0.456 (0.121, 0.698) 0.688 (0.409, 0.850) 0.622 (0.402, 0.797)
Adipate 0.731 (0.507, 0.862) 0.197 (0.207, 0.544) 0.307 (0.057, 0.572)
Alanine 0.533 (0.220, 0.747) 0.392 (0.005, 0.677) 0.355 (0.057, 0.572)
Arginine 0.614 (0.331, 0.796) 0.380 (0.009, 0.670) 0.390 (0.138, 0.637)
Asparagine 0.742 (0.525, 0.868) 0.709 (0.443, 0.861) 0.540 (0.301, 0.744)
Aspartate 0.676 (0.423, 0.832) 0.551 (0.207, 0.774) 0.483 (0.237, 0.705)
Betaine 0.626 (0.348, 0.803) 0.463 (0.091, 0.722) 0.579 (0.348, 0.770)
Cho 0.667 (0.409, 0.827) 0.810 (0.616, 0.912) 0.461 (0.212, 0.690)
Creatine 0.526 (0.210, 0.742) 0.741 (0.494, 0.877) 0.652 (0.440, 0.815)
Ethanolamine 0.791 (0.606, 0.895) 0.754 (0.518, 0.884) 0.633 (0.415, 0.803)
Fumarate 0.601 (0.312, 0.788) 0.348 (0.046, 0.649) 0.291 (0.043, 0.559)
Glucose 0.523 (0.206, 0.741) 0.639 (0.333, 0.823) 0.556 (0.321, 0.755)
Glutamate 0.597 (0.307,0.785) 0.376 (0.014, 0.667) 0.422 (0.171, 0.661)
Glutamine 0.512 (0.154, 0.751) 0.525 (0.172, 0.759) 0.599 (0.377, 0.779)
Glycerol 0.577 (0.279, 0.773) 0.619 (0.304, 0.812) 0.613 (0.390. 0.791)
Glycine 0.698 (0.455, 0.844) 0.553 (0.209, 0.775) 0.574 (0.342, 0.766)
GPC 0.729 (0.504, 0.861) 0.703 (0.433, 0.857) 0.786 (0.630, 0.893)
Histidine 0.733 (0.512, 0.864) 0.547 (0.201, 0.771) 0.434 (0.183, 0.670)
Isoleucine 0.672 (0.417, 0.829) 0.559 (0.218, 0.778) 0.547 (0.310, 0.749)
Lactate 0.561 (0.257, 0.764) 0.642 (0.338, 0.825) 0.404 (0.152, 0.648)
Leucine 0.721 (0.491, 0.857) 0.667 (0.377, 0.838) 0.487 (0.241, 0.708)
Lysine 0.702 (0.462, 0.846) 0.740 (0.494, 0.877) 0.619 (0.398, 0.795)
Methionine 0.697 (0.454, 0.843) 0.568 (0.230, 0.783) 0.473 (0.225, 0.698)
PC 0.194 (0.173, 0.514) 0.268 (0.134, 0.594) 0.391 (0.139, 0.639)
PE 0.241 (0.125, 0.549) 0.218 (0.186, 0.559) 0.248 (0.003, 0.523)
Phenylalanine 0.735 (0.514, 0.864) 0.760 (0.528, 0.887) 0.640 (0.425, 0.808)
Proline 0.489 (0.155, 0.722) 0.631 (0.313, 0.821) 0.408 (0.151, 0.656)
Serine 0.550 (0.242, 0.757) 0.427 (0.046, 0.699) 0.454 (0.205, 0.685)
Taurine 0.611 (0.327, 0.794) 0.495 (0.132, 0.741) 0.520 (0.278, 0.731)
tCho 0.530 (0.215, 0.745) 0.498 (0.136, 0.743) 0.448 (0.199, 0.681)
Threonine 0.563 (0.260, 0.765) 0.630 (0.320, 0.818) 0.515 (0.273, 0.728)
Tyrosine 0.712 (0.478, 0.852) 0.700 (0.427, 0.855) 0.574 (0.341, 0.766)
Uracil 0.560 (0.256, 0.763) 0.716 (0.455, 0.864) 0.531 (0.291, 0.738)
Valine 0.713 (0.480, 0.853) 0.629 (0.318, 0.817) 0.546 (0.309, 0.748)
m-Ins 0.632 (0.358, 0.806) 0.545 (0.199, 0.770) 0.636 (0.419, 0.806)
All specimen types include CNB specimens, central surgical specimens, and peripheral surgical specimens. Cho¼ choline, CI¼ confidence
interval, CNB¼ core-needle biopsy, GPC¼ glycerophosphocholine, HR-MAS¼ high-resolution magic angle spinning, ICC¼ intraclass correlation
sph
he s
Park et al Medicine  Volume 95, Number 15, April 2016For multivariate analysis, PLS-DA models were produced
separately for each specimen type (in vivo CNB specimens,
central surgical specimens, and peripheral surgical specimens).
In all 3 specimen types, PLS-DA models exhibited the highest
sensitivity for discriminating HER2-positive tumors from
HER2-negative tumors, with a range of 75.0% to 80.0%
(Table 4, Figure 3). Corresponding PLS-DA loading plots
showed that PC and glycine were contributing metabolites
for the discrimination between HER2-positive and HER2-
negative tumors. Based on the PLS-DA loading plots, PC,
glycine, and Cho were the contributing metabolites for the
discrimination between PR-positive and PR-negative tumors
(data not shown). In all 3 specimen types, PLS-DA showed the
lowest sensitivity and the highest specificity in discriminating
coefficient, m-Ins¼myo-inositol, MR¼magnetic resonance, PC¼ pho
men, Speriphery¼ peripheral surgical specimen, tCho¼ total choline (tER-positive tumors from ER-negative tumors, with a range of
47.1% to 66.7% and 62.5% to 90.0%, respectively. Correspond-
ing PLS-DA loading plots showed that PC and glycine were the
4 | www.md-journal.comocholine, PE¼ phosphoethanolamine, Scenter¼ central surgical speci-
um of Cho, PC, and GPC).contributing metabolites in the discrimination of tumors accord-
ing to ER status (data not shown).
DISCUSSION
To support prognostication and personalized treatment
strategies based on the results from a single tumor biopsy
sample, it is critical to investigate the possible influences from
specimen-related variables on HR-MASMR spectroscopy data.
In our study, most of the HR-MAS MR spectroscopic values
showed moderate to substantial agreement between the tumor
center and periphery (94.3%) and between the CNB and central
surgical specimens (82.9%). Our study results suggest that
overall, intratumoral location and biospecimen type have a
limited influence on HR-MAS MR spectroscopy data in breast
cancer and thus, interpretation based on a single tissue sample is
feasible for most metabolites.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. Heatmap showing metabolite concentrations for each tissue sample. Each column represents 1 tissue sample and each row
n; ‘
qui
we
Medicine  Volume 95, Number 15, April 2016 Intratumoral Agreement of Breast Cancer Metabolic CharacterizationHowever, concentrations of PC and PE were most affected
represents a different metabolite. ‘‘-n,’’ core needle biopsy specime
Lactate is not shown because a muchwider scale range would be re
would obscure differences in other metabolite concentrations betby specimen type and did not agree between the tumor center
and periphery or between CNB and central surgical specimens.
In in vivo 31P MR spectroscopy, PC and PE constitute a mixed
FIGURE 2. HR-MASMR spectra of breast cancer tissue obtained from a
PR-negative, HER2-positive, and tumor size 1.9 cm). PC, Cho, and G
the CNB specimen, 0.12, 0.05, and 0.10 for the central surgical
specimen, respectively. (A) HR-MAS MR spectra of the CNB specimen
specimen, all obtained from the primary breast cancer. Cho¼ cho
glycerophosphcholine, HER2¼human epidermal growth factor rece
magnetic resonance, PC¼phosphocholine, PR¼progesterone recept
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.phosphomonoester (PME) signal that has been shown to be
‘-c,’’ central surgical specimen; ‘‘-p,’’ peripheral surgical specimen.
red to express its higher range of values (maximum value: 70), and
en samples.elevated in many types of cancer cells and to correlate with
treatment outcome.20 A recent study on 31P HR-MAS MR
spectroscopy found that PE levels were significantly decreased
42-year-old woman with invasive ductal carcinoma (ER-negative,
PC levels by relative quantification were 0.10, 0.03, and 0.16 for
specimen, and 0.06, 0.03, and 0.11 for the periphery surgical
, (B) the central surgical specimen, and (C) the peripheral surgical
line, CNB¼ core-needle biopsy, ER¼ estrogen receptor, GPC¼
ptor 2, HR-MAS¼high-resolution magic angle spinning, MR¼
or.
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TABLE 3. Difference of HR-MAS MR Spectroscopic Values Between Specimen Types
Metabolite CNB Central Peripheral
P Value
Scenter Vs Speriphery CNB Vs Scenter
Acetate 0.248 0.251 0.297 0.230 0.241 0.294 0.765 0.380
Adipate 0.191 0.444 0.277 0.490 0.263 0.865 0.848 0.288
Alanine 1.022 0.818 1.137 0.876 1.002 0.849 0.415 0.583
Arginine 0.530 0.358 0.597 0.477 0.585 0.427 0.820 0.443
Asparagine 0.437 0.274 0.519 0.359 0.428 0.265 0.166 0.413
Aspartate 0.463 0.290 0.591 0.433 0.457 0.332 0.086 0.773
Betaine 0.158 0.181 0.265 0.409 0.131 0.227 0.132 0.247
Cho 0.345 0.373 0.556 0.619 0.362 0.594 0.198 0.577
Creatine 0.786 0.684 0.969 0.734 0.722 0.767 0.155 0.444
Ethanolamine 0.217 0.168 0.359 0.331 0.288 0.370 0.462 0.255
Fumarate 0.072 0.048 0.088 0.068 0.066 0.043 0.051 0.776
Glucose 0.056 0.702 0.705 0.708 0.509 0.480 0.084 0.920
Glutamate 1.241 1.033 1.605 1.195 1.331 1.069 0.149 0.671
Glutamine 1.237 0.892 1.048 0.816 0.847 0.781 0.703 0.009
Glycerol 0.391 0.329 0.504 0.355 0.390 0.351 0.153 0.950
Glycine 2.586 1.820 3.156 2.161 2.845 1.918 0.349 0.825
GPC 0.293 0.298 0.336 0.318 0.291 0.359 0.227 0.831
Histidine 0.155 0.123 0.185 0.133 0.149 0.114 0.081 0.416
Isoleucine 0.283 0.196 0.376 0.271 0.360 0.360 0.976 0.711
Lactate 9.838 6.977 12.067 11.159 12.498 14.962 0.422 0.492
Leucine 0.653 0.533 0.904 0.737 0.727 0.630 0.187 0.905
Lysine 0.334 0.267 0.558 0.502 0.397 0.320 0.172 0.278
Methionine 0.124 0.088 0.201 0.253 0.133 0.090 0.233 0.741
PC 0.603 0.566 0.840 0.781 0.651 0.646 0.788 0.506
PE 1.324 0.956 1.489 1.012 1.079 0.748 0.080 0.836
Phenylalanine 0.262 0.190 0.369 0.342 0.283 0.192 0.291 0.691
Proline 0.582 0.434 0.901 0.778 0.521 0.407 0.011 0.329
Serine 1.142 0.967 1.389 0.961 1.204 0.789 0.210 0.945
Taurine 2.744 1.917 3.437 0.961 2.810 2.039 0.091 0.534
tCho 1.241 1.004 1.707 1.431 1.304 1.175 0.338 0.539
Threonine 0.627 0.482 0.677 0.493 0.529 0.309 0.092 0.506
Tyrosine 0.258 0.183 0.311 0.200 0.272 0.178 0.458 0.655
Uracil 0.206 0.175 0.208 0.188 0.168 0.118 0.876 0.040
Valine 0.589 0.408 0.725 0.478 0.656 0.414 0.359 0.652
m-Ins 1.015 1.139 1.402 1.269 1.067 1.099 0.050 0.450
Data are shown as mean standard deviation. Cho¼ choline, CNB¼ core-needle biopsy, GPC¼ glycerophosphocholine, HR-MAS¼ high-
resolution magic angle spinning, ICC¼ intraclass correlation coefficient, m-Ins¼myo-inositol, MR¼magnetic resonance, PC¼ phosphocholine,
PE¼ phosphoethanolamine, Scenter¼ central surgical specimen, Speriphery¼ peripheral surgical specimen, tCho¼ total choline (the sum of Cho,
PC, and GPC).
TABLE 4. Diagnostic Performance of PLS-DA for Differentiating Hormone Receptor Status According to Specimen Type
Specimen Type ERpos Vs ERneg, % PRpos Vs PRneg, % HER2pos Vs HER2neg, %
CNB Sensitivity 47.1 90.0 80.0
Specificity 62.5 66.7 55.0
Scenter Sensitivity 66.7 72.7 75.0
Specificity 90.0 75.0 60.9
Speriphery Sensitivity 55.0 60.0 75.0
Specificity 80.0 60.0 54.5
CNB¼ core-needle biopsy, ERneg¼ER negative, ERpos¼ER positive, HER2neg¼HER2 negative, HER2pos¼HER2 positive, PLS-DA¼ partial
least squares discriminant analysis, PRneg¼PR negative, PRpos¼PR positive, Scenter¼ central surgical specimen, Speriphery¼ peripheral surgical
specimen.
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FIGURE 3. PLS-DA score plots of the HR-MASMR spectra for ER, PR, HER2 status, and loading plots of HER2-positive versus HER-negative
breast cancers according to each specimen type. (A–C) PLS-DA score plot for ER status obtained from (A) CNB samples, (B) central
surgical samples, and (C) peripheral surgical samples. (D–F) PLS-DA score plot for PR status obtained from (D) CNB samples, (E) central
surgical samples, and (F) peripheral surgical samples. (G–I) PLS-DA score plot for HER2 status obtained from (G) CNB samples, (H)
central surgical samples, and (I) peripheral surgical samples. (J–L) Loading S-plots of the HR-MAS MR spectra for the discrimination of
HER2-positive versus HER2-negative breast cancers in (J) CNB samples, (K) central surgical samples, and (L) peripheral surgical samples.
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inhibitor BEZ235, whereas PC and GPC levels were
increased.21 As the P13K pathway is a major target for antic-
ancer drug development, our results may imply that sampling
from several different tumor locations may be necessary when
monitoring treatment response based on 31P MR spec-
troscopy.22 In 1H MR spectroscopy, the elevation of PC and
tCho levels has also been widely established as a characteristic
of cancer cells. The increased tCho levels detected in vivo are
primarily due to an increase in PC levels, with a GPC to PC
switch having been reported as an early phenotypic change in
breast tumor cell lines during carcinogenesis.23,24 Previous
research has shown that the treatment of cancer cells with
P13K inhibitors induces a decrease in PC and tCho levels
detected by 1H MR spectroscopy, and that a strong correlation
is found between PC concentrations and choline kinase a
expression.22 Based on this accumulating research, investi-
gators have suggested the potential role of MR spectroscopy
as a noninvasive biomarker for P13K inhibition and tumor
response in clinical trials using P13K inhibitors.22,25 Our results
imply that further validation is needed prior to the application of
MR spectroscopy for this purpose, as PC measurements from a
single tissue sample may not be reliable. In contrast, Cho and
GPC levels had moderate to almost perfect agreement, and
thus appear to be less affected by intratumoral location and
biospecimen type.
Multivariate analysis is commonly used for the interpret-
CNB¼ core-needle biopsy, ER¼ estrogen receptor, HER2¼hum
magic angle spinning, MR¼magnetic resonance, PLS-DA¼partiaation of HR-MAS MR spectral data and can identify trends and
clusters related to the sample properties based on the combined
influence of metabolites.26 Recent studies have shown that
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.multivariate models can separate breast cancer samples by
hormone receptor status (ER, PR, HER2, and triple negativity)
and according to pathologic response to neoadjuvant che-
motherapy.4,5,27 In our study, PLS-DA models showed similar
patterns regardless of specimen type, demonstrating the highest
sensitivity in discriminating HER2-positive tumors from
HER2-negative tumors and the lowest sensitivity in separating
ER-positive and ER-negative tumors. The corresponding load-
ing plots demonstrated similar contributing metabolites to the
results of Cao et al,4 with elevated glycine levels in ER-
negative, PR-negative, and HER2-positive tumors. Our study
results imply that multivariate analysis of HR-MAS MR spec-
troscopic profiles showed similar results regardless of intratu-
moral location and biospecimen type, and, thus, can be readily
applied in the metabolic characterization of breast cancer
biopsy samples.
Our study had several limitations. First, because of its
prospective design, our study included a small number of
patients and information on long-term follow-up was not avail-
able. Therefore, we could not evaluate correlations between
HR-MAS MR spectroscopy data and overall or disease-free
survival. We believe that an interesting future topic would be
establishing the prognostic value of HR-MASMR spectroscopy
in patients with breast cancer. Second, in vivo CNB samples
were not available or excluded due to a lack of tumor cells in
approximately 25.7% of the patients and could have affected
our analysis according to specimen types, especially the
epidermal growth factor receptor 2, HR-MAS¼high-resolution
ast squares discriminant analysis, PR¼progesterone receptor.analysis between all 3 specimen types. Third, we compared
HR-MAS MR spectroscopic values between different portions
of a mass, and not among individual cancer cells. This may
www.md-journal.com | 7
partly explain the high overall level of intratumoral agreement
in our results; however, the aim of our study was to investigate
the influence of specimen-related variables on the metabolic
assessment of breast cancer based on a single tissue sample, not
at the cellular level, to facilitate its clinical implementation.
In summary, this study demonstrated that overall, intratu-
moral location and biospecimen type, have limited influence on
HR-MAS MR spectroscopic profiles in the metabolic charac-
terization of breast cancer. However, some metabolites are
differentially expressed across different specimen types and
caution is recommended in clinical decision-making based
solely on metabolite concentrations, especially of PC and
Park et alPE. With further validation by larger studies, 1H HR-MAS
MR spectroscopy can be implemented in order to personalize
treatment based on data from a single tissue sample.
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